EXOCEL BIO
Patrick Retif, CEO
info@exocelbio.com
Founded in 2020, EXOCEL BIO is on a mission to make cellular regeneration a reality through its nanoparticle technology platform. Specifically, the company is focused on exosomes nanoparticles or sometimes referred to as “signalosomes” due to the fact they seek out specific cellular targets and, upon arriving at their intended destination, can transfer their cargo to recipient cells or activate signaling pathways in order to change the behavior of the recipient cell.
The company manufactures its product EXOVEX using mesenchymal stem cells (MSCs) harvested from a single placental chorion per each batch of exosomes. EXOVEX exosomes are tested to be completely free of DNA, and all donor tissue is screened for pathogens and tested to ensure that it is negative for communicable diseases. This meticulous process assures that EXOVEX is made of comprehensively screened, safe, and effective exosomes.
Currently, EXOVEX is for healthcare professional use only as a topical application for skin and hair rejuvenation, pain management, or other applications per physician discretion. In addition to the EXOVEX Serum, the company also has the EXOVEX Kit, which includes the Serum as well as a proprietary driver cream created in a compounding pharmacy and an exfoliating cream. The Kit can be used as a topical applied post procedure, such as from laser, micro-needling, or platelet-rich plasma (PRP), in order to shorten recovery time.
Clinical trials are also underway to test whether exosomes can serve as a therapy to alter the inflammatory response. Early findings suggest that MSC-derived exosomes can modulate the phenotype of macrophages. This is the likely mechanism of action that exosomes exert on inflammation, since macrophages play a pivotal role in regulating immune responses.
